Maren Cam1, Manish Charan1, Alessandra M Welker2, Piyush Dravid1, Adam W Studebaker1, Jeffrey R Leonard1, Christopher R Pierson3, Ichiro Nakano4, Christine E Beattie5, Eugene I Hwang6, Madhuri Kambhampati7, Javad Nazarian7, Jonathan L Finlay8,9, Hakan Cam1,9. 1. Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio. 2. Cancer Center and Regenerative Medicine, Massachusetts General Hospital, Boston. 3. Department of Pathology & Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio. 4. Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama. 5. Department of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, Ohio. 6. Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC. 7. Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC. 8. Neuro-oncology Program, Nationwide Children's Hospital, Columbus, Ohio. 9. Department of Pediatrics, The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND: Glioblastoma (GBM) remains one of the least successfully treated cancers. It is essential to understand the basic biology of this lethal disease and investigate novel pharmacological targets to treat GBM. The aims of this study were to determine the biological consequences of elevated expression of ΔNp73, an N-terminal truncated isoform of TP73, and to evaluate targeting of its downstream mediators, the angiopoietin 1 (ANGPT1)/tunica interna endothelial cell kinase 2 (Tie2) axis, by using a highly potent, orally available small-molecule inhibitor (rebastinib) in GBM. METHODS: ΔNp73 expression was assessed in glioma sphere cultures, xenograft glioblastoma tumors, and glioblastoma patients by western blot, quantitative reverse transcription PCR, and immunohistochemistry. Immunoprecipitation, chromatin immunoprecipitation (ChiP) and sequential ChIP were performed to determine the interaction between ΔNp73 and E26 transformation-specific (ETS) proto-oncogene 2 (ETS2) proteins. The oncogenic consequences of ΔNp73 expression in glioblastomas were examined by in vitro and in vivo experiments, including orthotopic zebrafish and mouse intracranial-injection models. Effects of rebastinib on growth of established tumors and survival were examined in an intracranial-injection mouse model. RESULTS: ΔNp73 upregulates both ANGPT1 and Tie2 transcriptionally through ETS conserved binding sites on the promoters by interacting with ETS2. Elevated expression of ΔNp73 promotes tumor progression by mediating angiogenesis and survival. Therapeutic targeting of downstream ΔNp73 signaling pathways by rebastinib inhibits growth of established tumors and extends survival in preclinical models of glioblastoma. CONCLUSION: Aberrant expression of ΔNp73 in GBM promotes tumor progression through autocrine and paracrine signaling dependent on Tie2 activation by ANGPT1. Disruption of this signaling by rebastinib improves tumor response to treatment in glioblastoma.
BACKGROUND:Glioblastoma (GBM) remains one of the least successfully treated cancers. It is essential to understand the basic biology of this lethal disease and investigate novel pharmacological targets to treat GBM. The aims of this study were to determine the biological consequences of elevated expression of ΔNp73, an N-terminal truncated isoform of TP73, and to evaluate targeting of its downstream mediators, the angiopoietin 1 (ANGPT1)/tunica interna endothelial cell kinase 2 (Tie2) axis, by using a highly potent, orally available small-molecule inhibitor (rebastinib) in GBM. METHODS: ΔNp73 expression was assessed in glioma sphere cultures, xenograft glioblastoma tumors, and glioblastomapatients by western blot, quantitative reverse transcription PCR, and immunohistochemistry. Immunoprecipitation, chromatin immunoprecipitation (ChiP) and sequential ChIP were performed to determine the interaction between ΔNp73 and E26 transformation-specific (ETS) proto-oncogene 2 (ETS2) proteins. The oncogenic consequences of ΔNp73 expression in glioblastomas were examined by in vitro and in vivo experiments, including orthotopic zebrafish and mouse intracranial-injection models. Effects of rebastinib on growth of established tumors and survival were examined in an intracranial-injection mouse model. RESULTS: ΔNp73 upregulates both ANGPT1 and Tie2 transcriptionally through ETS conserved binding sites on the promoters by interacting with ETS2. Elevated expression of ΔNp73 promotes tumor progression by mediating angiogenesis and survival. Therapeutic targeting of downstream ΔNp73 signaling pathways by rebastinib inhibits growth of established tumors and extends survival in preclinical models of glioblastoma. CONCLUSION: Aberrant expression of ΔNp73 in GBM promotes tumor progression through autocrine and paracrine signaling dependent on Tie2 activation by ANGPT1. Disruption of this signaling by rebastinib improves tumor response to treatment in glioblastoma.
Authors: E Audero; I Cascone; I Zanon; S C Previtali; R Piva; D Schiffer; F Bussolino Journal: Arterioscler Thromb Vasc Biol Date: 2001-04 Impact factor: 8.311
Authors: Véronique Diéras; Hans Wildiers; Jacek Jassem; Luc Y Dirix; Jean-Paul Guastalla; Petri Bono; Sara A Hurvitz; Anthony Gonçalves; Gilles Romieu; Steven A Limentani; Guy Jerusalem; K C Lakshmaiah; Henri Roché; Pedro Sánchez-Rovira; Tadeusz Pienkowski; Miguel Ángel Seguí Palmer; Ai Li; Yu-Nien Sun; Cheryl A Pickett; Dennis J Slamon Journal: Breast Date: 2015-03-05 Impact factor: 4.380
Authors: C Suri; P F Jones; S Patan; S Bartunkova; P C Maisonpierre; S Davis; T N Sato; G D Yancopoulos Journal: Cell Date: 1996-12-27 Impact factor: 41.582
Authors: Alessandro Rufini; Massimiliano Agostini; Francesca Grespi; Richard Tomasini; Berna S Sayan; Maria Victoria Niklison-Chirou; Franco Conforti; Tania Velletri; Antonio Mastino; Tak W Mak; Gerry Melino; Richard A Knight Journal: Genes Cancer Date: 2011-04
Authors: Kevin G Peters; Christopher D Kontos; P Charles Lin; Adrianne L Wong; Prema Rao; Liwen Huang; Mark W Dewhirst; Sabita Sankar Journal: Recent Prog Horm Res Date: 2004
Authors: Maarten Niemantsverdriet; Peter Nagle; Roland K Chiu; Johannes A Langendijk; Harm H Kampinga; Robert P Coppes Journal: PLoS One Date: 2012-12-07 Impact factor: 3.240
Authors: Svetlana Zvereva; Aleksandra Dalina; Igor Blatov; Julian M Rozenberg; Ilya Zubarev; Daniil Luppov; Alexander Bessmertnyi; Alexander Romanishin; Lamak Alsoulaiman; Vadim Kumeiko; Alexander Kagansky; Gerry Melino; Carlo Ganini; Nikolai A Barlev Journal: Biol Direct Date: 2021-11-08 Impact factor: 4.540
Authors: Julian M Rozenberg; Svetlana Zvereva; Alexandra Dalina; Igor Blatov; Ilya Zubarev; Daniil Luppov; Alexander Bessmertnyi; Alexander Romanishin; Lamak Alsoulaiman; Vadim Kumeiko; Alexander Kagansky; Gerry Melino; Nikolai A Barlev Journal: Cells Date: 2021-12-13 Impact factor: 6.600